| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | -4.5% | RBC Capital | $23 → $7 | Downgrades | Outperform → Sector Perform |
| 05/10/2023 | 213.78% | RBC Capital | $24 → $23 | Maintains | Outperform |
| 05/10/2023 | 159.21% | Wedbush | $20 → $19 | Maintains | Outperform |
| 05/04/2023 | — | Goldman Sachs | Upgrades | Sell → Neutral | |
| 03/15/2023 | 227.42% | RBC Capital | → $24 | Reiterates | → Outperform |
| 12/09/2022 | 200.14% | SVB Leerink | $30 → $22 | Maintains | Outperform |
| 12/08/2022 | 227.42% | RBC Capital | $29 → $24 | Maintains | Outperform |
| 08/09/2022 | 254.71% | Wedbush | $21 → $26 | Maintains | Outperform |
| 06/10/2022 | 186.49% | Wedbush | → $21 | Initiates Coverage On | → Outperform |
| 05/24/2022 | -18.14% | Goldman Sachs | $8 → $6 | Maintains | Sell |
| 05/10/2022 | 309.28% | SVB Leerink | $36 → $30 | Maintains | Outperform |
| 05/02/2022 | 309.28% | RBC Capital | → $30 | Initiates Coverage On | → Outperform |
| 01/19/2022 | 36.43% | Goldman Sachs | → $10 | Initiates Coverage On | → Sell |
| 04/20/2021 | 391.13% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
| 04/20/2021 | 281.99% | Goldman Sachs | → $28 | Initiates Coverage On | → Neutral |
| 04/20/2021 | 472.99% | Piper Sandler | → $42 | Initiates Coverage On | → Overweight |
What is the target price for Design Therapeutics (DSGN)?
The latest price target for Design Therapeutics (NASDAQ: DSGN) was reported by RBC Capital on August 15, 2023. The analyst firm set a price target for $7.00 expecting DSGN to fall to within 12 months (a possible -4.50% downside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Design Therapeutics (DSGN)?
The latest analyst rating for Design Therapeutics (NASDAQ: DSGN) was provided by RBC Capital, and Design Therapeutics downgraded their sector perform rating.
When is the next analyst rating going to be posted or updated for Design Therapeutics (DSGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
Is the Analyst Rating Design Therapeutics (DSGN) correct?
While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a downgraded with a price target of $23.00 to $7.00. The current price Design Therapeutics (DSGN) is trading at is $7.33, which is out of the analyst's predicted range.